Observational
COVID-19 in Patients with HIV
 

Investigator: Debra Powell, MD

The purpose of his study is to characterize the clinical presentation and course of COVID-19 in patients with HIV.

Learn more about the COVID HIV trial or call the Clinical Trials Office at 484-628-8585.

IMPACC

"Immunophenotyping Assessment in a COVID-19 COHORT"

Investigator: Debra Powell, MD

The purpose of this observational study is to describe the relationship between the body's immune responses and the severity of COVID-19 in patients.

Learn more about the IMPACC trial.

View on NIH.gov and ClinicalTrials.gov

Study is closed to enrollment.

Treatment
ACTIV-1 IM

Immune Modulators for Treating COVID-19

Investigator: Daron Kahn, MD

The purpose of this study is to evaluate multiple investigational drugs for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome due to COVID-19. Each agent will be evaluated as add-on therapy to the standard of care (SOC) in accordance with national or local guidelines. SOC may include Remdesivir. The study is adaptive with the goal of discontinuing those study medications with lower probabilities of success to utilize trial resources more effectively for the remaining agents.

Learn more about the ACTIV-1 IM trial.

View on ClinicalTrials.gov, NIH.gov, and ACTIV-1.org or call the Clinical Trials Office at 484-628-8585 for more information.

COVID-19 Vaccine in Pregnant Women

A Phase 2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Investigator: Daniel Jiang, MD

The purpose of this study is to evaluate the safety and tolerability of a COVID-19 vaccine when administered to maternal participants who might be at increased risk for severe illness from COVID-19 compared to non-pregnant women. Pregnant women will be vaccinated at 24-to-34 weeks’ gestation.

Learn more about the COVID-19 Maternal Vaccine trial.

View on ClinicalTrials.gov and Pfizer.com, or call the Clinical Trials Office at 484-628-8585 for more information.

ACTIV-4c

(Accelerating COVID-19 Therapeutic Interventions and Vaccines) Post-hospital Thrombosis Prevention Study

Investigator: Daniel Forman, DO

The purpose of this study is to compare the effectiveness and safety of antithrombotic therapy versus no antithrombotic therapy for prevention of symptomatic deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction (among others) after hospitalization lasting 48 hours or longer for COVID-19.

Learn more about the ACTIV-4c trial.

View on ClinicalTrials.gov, NIH.gov, and CombatCOVID.HHS.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Plasma Adsorption in Patients with Confirmed COVID-19 Infection
 

Investigator: Trudy Demko, MD

The purpose of this study is to evaluate the ability of the D2000 Cartridge, for use with the Spectra Optia Apheresis System, to reduce morbidity and mortality in SARs-CoV-2 infected patients admitted to Intensive Care for management of respiratory failure.

Learn more about the Plasma Adsorption trial.

View on ClinicalTrials.gov and Terumo.com, or call the Clinical Trials Office at 484-628-8585 for more information.